Thomas Bateman
Merck & Co.
18 Papers
150 Citations
Thomas Bateman is an academic researcher from Merck & Co.. The author has contributed to research in topics: Mineralocorticoid receptor & Metabolite. The author has an hindex of 10, co-authored 18 publications.
Chat about Author
Papers
Application of chimeric mice with humanized liver for study of human-specific drug metabolism.
TL;DR: The data indicate that the chimeric mice with humanized liver have the potential to be a useful tool for the prediction of human-specific metabolism of xenobiotics and warrant further investigation.
40
Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.
Jason M. Cox,Hong D. Chu,Christine Yang,Hong C. Shen,Zhicai Wu,Jaume Balsells,Alejandro Crespo,Patricia Brown,Beata Zamlynny,Judyann Wiltsie,Joseph Clemas,Jack Gibson,Lisa Contino,JeanMarie Lisnock,Gaochao Zhou,Margarita Garcia-Calvo,Thomas Bateman,Ling Xu,Xinchun Tong,Martin Crook,Peter J. Sinclair +20 more
TL;DR: Structural-activity relationship efforts focused on improving lipophilic ligand efficiency (LLE) while maintaining nuclear hormone receptor selectivity and reasonable pharmacokinetic profiles.
26
Discovery of imidazole carboxamides as potent and selective CCK1R agonists
Cheng Zhu,Alexa Hansen,Thomas Bateman,Zhesheng Chen,Tom G. Holt,James Hubert,Bindhu V. Karanam,Susan J. Lee,Jie Pan,Su Qian,Vijay Bhasker G. Reddy,Marc L. Reitman,Alison M. Strack,Vincent Tong,Drew T. Weingarth,Michael Wolff,Doug J. MacNeil,Ann E. Weber,Joseph L. Duffy,Scott D. Edmondson +19 more
TL;DR: SAR studies led to the discovery and optimization of a novel class of 1,2-diaryl imidazole carboxamides and diaryl pyrazole 3 as a selective albeit modest cholecystokinin 1 receptor (CCK1R) agonist.
24
Development of a novel tricyclic class of potent and selective FIXa inhibitors.
Dongfang Meng,Patrick Andre,Thomas Bateman,Richard A. Berger,Yi-Heng Chen,Kunal Desai,Sunita V. Dewnani,Kenneth P. Ellsworth,Daming Feng,Wayne M. Geissler,Liangqin Guo,Alan Hruza,Tianying Jian,Hong Li,Joe Metzger,Dann L. Parker,Paul Reichert,Edward C. Sherer,Cameron J. Smith,Lisa M. Sonatore,Richard Tschirret-Guth,Jane Y. Wu,Jiayi Xu,Ting Zhang,Louis-Charles Campeau,Robert K. Orr,Marc Poirier,Jamie McCabe-Dunn,Kazuto Araki,Teruyuki Nishimura,Isao Sakurada,Tomokazu Hirabayashi,Harold B. Wood +32 more
TL;DR: Using structure based drug design, a novel class of potent coagulation factor IXa (FIXa) inhibitors was designed and synthesized and high selectivity over FXa inhibition was achieved.
20
Lymphatic Absorption, Metabolism, and Excretion of a Therapeutic Peptide in Dogs and Rats
Yan Zou,Thomas Bateman,Christine Adreani,Xiaolan Shen,P Cunningham,Bo Wang,Tu Trinh,Amy Christine,Xuening Hong,Christian N. Nunes,Christopher V. Johnson,Andy Shiqiang Zhang,Steve J. Staskiewicz,Matthew P. Braun,Sanjeev Kumar,Vijay Bhasker G. Reddy +15 more
TL;DR: Analysis of injection site s.c.v. tissue showed significant metabolism of [3H]MRL-1, which provides an explanation for the <100% bioavailability of therapeutic proteins and peptides after s.
19